{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T19:26:10Z","timestamp":1769282770455,"version":"3.49.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Reprod. Health"],"abstract":"<jats:p>Menopause is a physiological and progressive phenomenon secondary to decreased ovarian follicular reserve that significantly affects the genital tract. Although postmenopausal vulvovaginal atrophy primarily affects postmenopausal women, it is also seen in premenopausal women. The hypoestrogenic condition results in hormonal and anatomical changes, with the main symptoms, are dryness, burning and genital irritation, decreased lubrication, urinary urgency, dysuria, and recurrent urinary tract infections. This review aims to update hormone therapy for urogenital atrophy, both local and systemic, and discusses the importance of understanding and the need for active treatment of this condition. The main therapeutic objective is the relief of symptoms, and hormonal therapy (HT) is still the most effective choice for treating clinical manifestations, despite the side effects of its use. HT should be used in an individualized way to the needs of the women and appropriate to the stage in which she is menopausal, perimenopausal, or after menopause.<\/jats:p>","DOI":"10.3389\/frph.2021.783247","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T14:12:03Z","timestamp":1638367923000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Hormonal Approach for Postmenopausal Vulvovaginal Atrophy"],"prefix":"10.3389","volume":"3","author":[{"given":"Ana Paula Ferreira","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayane Cristine Alves","family":"Sarmento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Vieira-Baptista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Jos\u00e9","family":"Eleut\u00e9rio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo Ney","family":"Cobucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Katherine","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","article-title":"Vulvovaginal atrophy terminology consensus conference panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women's sexual health and the North American menopause society","volume":"21","author":"Portman","year":"2014","journal-title":"Menopause"},{"key":"B2","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1080\/09513590.2021.1931100","article-title":"Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy","volume":"37","author":"P\u00e9rez-L\u00f3pez","year":"2021","journal-title":"Gynecol Endocrinol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.ajog.2016.07.045","article-title":"Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management","volume":"215","author":"Gandhi","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"B4","first-page":"305","article-title":"Urogenital atrophy: diagnosis, sequelae, and management","volume":"2","author":"Keil","year":"2002","journal-title":"Curr Womens Health Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/2053369119866341","article-title":"Therapies for the management of genitourinary syndrome of menopause","volume":"26","author":"Palacios","year":"2020","journal-title":"Post Reprod Health."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1111\/jsm.12235","article-title":"The CLOSER (CLarifying Vaginal Atrophy's Impact OnSEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners","volume":"10","author":"Nappi","year":"2013","journal-title":"J Sex Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1097\/GME.0b013e3182a122c2","article-title":"Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American menopause society","volume":"20","year":"2013","journal-title":"Menopause"},{"key":"B8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/GME.0000000000000921","article-title":"The 2017 hormone therapy position statement of The North American menopause society","volume":"24","year":"2017","journal-title":"Menopause"},{"key":"B9","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1080\/09513590.2021.1943346","article-title":"Management of postmenopausal vulvovaginal atrophy: recommendations of the international society for the study of Vulvovaginal disease","volume":"37","author":"Perez-Lopez","year":"2021","journal-title":"Gynecol Endocrinol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/humupd\/dmab026","article-title":"Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice","volume":"27","author":"Genazzani","year":"2021","journal-title":"Hum Reprod Update."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e17472","DOI":"10.7759\/cureus.17472","article-title":"Role of gut microbiotadysbiosis in breast cancer and novel approaches in prevention, diagnosis, and treatment","volume":"13","author":"Ruo","year":"2021","journal-title":"Cureus."},{"key":"B12","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/gme.0b013e318247f07a","article-title":"Oral micronized progesterone for vasomotor symptoms\u2014a placebo-controlled randomized trial in healthy postmenopausal women","volume":"19","author":"Hitchcock","year":"2012","journal-title":"Menopause."},{"key":"B13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/13697137.2018.1476483","article-title":"Progesterone, progestins and the breast in menopause treatment","volume":"21","author":"Gompel","year":"2018","journal-title":"Climacteric."},{"key":"B14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3109\/09513590.2012.705390","article-title":"Progesterone for hot flush and night sweat treatment \u2013 effectiveness for severe vasomotor symptoms and lack of withdrawal rebound","volume":"28","author":"Prior","year":"2018","journal-title":"Gynecol Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1743-6109.2008.01121.x","article-title":"Testosterone therapy in women with gynecological and sexual disorders: a triumph of clinical endocrinology from 1938 to 2008","volume":"6","author":"Traish","year":"2009","journal-title":"J Sex Med"},{"key":"B16","article-title":"Testosterona treatment of male hypogonadism","author":"Peter","year":"2021","journal-title":"UpToDate"},{"key":"B17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ecl.2015.05.001","article-title":"Menopausal symptoms and their management","volume":"44","author":"Santoro","year":"2015","journal-title":"Endocrinol Metab Clin North Am."},{"key":"B18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/GME.0000000000001221","article-title":"A systematic review of the efficacy an safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause","volume":"26","author":"Biehl","year":"2019","journal-title":"Menopause"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/j.mayocp.2017.08.019","article-title":"Genitourinary syndrome of menopause: management strategies for the clinician","volume":"92","author":"Faubion","year":"2017","journal-title":"Clin Proc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1016\/j.clbc.2019.07.007","article-title":"The safety of local hormonal treatment for vulvovaginal atrophy in women with estrogen receptor-positive breast cancer who are on adjuvant aromatase inhibitor therapy: meta-analysis","volume":"19","author":"Pavlovic","year":"2019","journal-title":"Clin Breast Cancer."},{"key":"B21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/GME.0000000000001497","article-title":"Efficacy and safety of ultra-low dose 0005% estriol vaginal gel for the treatment of vulvovaginalatrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial Menopause","volume":"27","author":"Hirschberg","year":"2020"},{"key":"B22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1515\/hmbci-2016-0042","article-title":"A low dose (65 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values","volume":"29","author":"Labrie","year":"2017","journal-title":"Horm Mol Biol Clin Investig."},{"key":"B23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0015-0282(02)02965-5","article-title":"Screening for androgen deficiency in women: methodological and interpretive issues","volume":"77","author":"Guay","year":"2002","journal-title":"FertilSteril."},{"key":"B24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00520-017-3878-2","article-title":"Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer."},{"key":"B25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/LGT.0b013e3182241f1a","article-title":"Vulvovaginal candidiasis in postmenopausal women: the role of hormone replacement therapy","volume":"15","author":"Fischer","year":"2011","journal-title":"J Low Genit Tract Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/GME.0000000000001138","article-title":"The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): international society for the study of women's sexual health (ISSWSH) expert consensus panel review","volume":"25","author":"Simon","year":"2018","journal-title":"Menopause."},{"key":"B27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1743-6109.2006.00212.x","article-title":"Vaginal application of testosterone: a study on pharmacokinetics and the sexual response in healthy volunteers","volume":"3","author":"Apperloo","year":"2006","journal-title":"J Sex Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/GME.0000000000001059","article-title":"Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study","volume":"25","author":"Fernandes","year":"2018","journal-title":"Menopause."},{"key":"B29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejogrb.2018.08.008","article-title":"AthanasiouS. Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: a systematic review and meta-analysis of randomized controlled trials","volume":"229","author":"Pitsouni","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1097\/01.gme.0000247016.41007.c9","article-title":"Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women","volume":"13","author":"Swanson","year":"2016","journal-title":"Menopause"},{"key":"B31","doi-asserted-by":"publisher","first-page":"8551","DOI":"10.3390\/ijms22168551","article-title":"Oxytocin and bone: review and perspectives","volume":"22","author":"Breuil","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1258\/mi.2011.011030","article-title":"Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study","volume":"17","author":"Jonasson","year":"2011","journal-title":"Menopause"},{"key":"B33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.6118\/jmm.2015.21.2.65","article-title":"The recent review of the genitourinary syndrome of menopause","volume":"21","author":"Hyun-Kyung","year":"2015","journal-title":"J Menopausal Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/2053369115577328","article-title":"Intravaginally applied oxytocin improves postmenopausal vaginal atrophy","volume":"21","author":"Al-saqi","year":"2015","journal-title":"Post Reprod Health"},{"key":"B35","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/GRF.0000000000000380","article-title":"Genitourinary syndrome of menopause","volume":"61","author":"Shifren","year":"2018","journal-title":"Clin Obstet Gynecol"}],"container-title":["Frontiers in Reproductive Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2021.783247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T14:12:05Z","timestamp":1638367925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2021.783247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":35,"alternative-id":["10.3389\/frph.2021.783247"],"URL":"https:\/\/doi.org\/10.3389\/frph.2021.783247","relation":{},"ISSN":["2673-3153"],"issn-type":[{"value":"2673-3153","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"article-number":"783247"}}